`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners
`
`Case IPR2021-00816
`Patent 9,220,631
`
`JOINT STIPULATION TO MODIFY
`DATE TO SERVE DEMONSTRATIVES ON
`OPPOSING COUNSEL
`
`
`
`
`
`IPR2021-00816
`U.S. Patent No. 9,220,631
`
`
`
`Pursuant to Order Setting Oral Argument (Paper 99, entered on June 27,
`
`2022), Patent Owners Novartis Pharma AG, Novartis Technology LLC, and
`
`Novartis Pharmaceuticals Corporation (collectively, “Novartis”) and Petitioner
`
`Regeneron Pharmaceuticals, Inc. (“Regeneron”) (Regeneron and Novartis,
`
`collectively, “Parties”) respectfully request that the Board accept the Parties’
`
`stipulation to modify the date of service of demonstratives on opposing counsel
`
`from July 12, 2022, to July 14, 2022. Paper 99 at 3 n.6.
`
` This stipulation does not affect or otherwise modify the dates for any other
`
`deadlines in the Schedule Order (Paper 14) or Order Setting Oral Argument (Paper
`
`99).
`
`Dated: July 6, 2022
`By:
`/Elizabeth J. Holland/
`
`Elizabeth J. Holland (Reg. No. 47,657)
`Lead Counsel for Patent Owners
`Allen & Overy LLP
`1221 Avenue of the Americas
`New York, NY 10020
`Phone: + 212 610 6365
`Elizabeth.Holland@allenovery.com
`
`
`
`
`
`/Anish R. Desai/
`By:
`
`Anish R. Desai (Reg. No. 73,760)
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`anish.desai@weil.com
`
`1
`
`
`
`IPR2021-00816
`U.S. Patent No. 9,220,631
`CERTIFICATE OF SERVICE
`A copy of this JOINT STIPULATION TO MODIFY DATE TO SERVE
`
`DEMONSTRATIVES ON OPPOSING COUNSEL has been served on
`
`Petitioner’s attorneys of record as follows via electronic mail:
`
`Elizabeth Stotland Weiswasser
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8022
`F: 212-310-8007
`elizabeth.weiswasser@weil.com
`USPTO Reg. No. 55,721
`Anish R. Desai
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`anish.desai@weil.com
`USPTO Reg. No. 73,760
`
`Natalie Kennedy
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`natalie.kennedy@weil.com
`USPTO Reg. No. 68,511
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2021-00816
`U.S. Patent No. 9,220,631
`
`
`Andrew Gesior
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`andrew.gesior@weil.com
`USPTO Reg. No. 76,588
`
`Brian E. Ferguson
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`brian.ferguson@weil.com
`USPTO Reg. No. 36,801
`
`Christopher M. Pepe
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`christopher.pepe@weil.com
`USPTO Reg. No. 73,851
`
`Regeneron.IPR.Service@weil.com
`
`Attorneys for Regeneron Pharmaceuticals, Inc.
`Dated: July 6, 2022
`By:
`/Frank ReDavid/
`Frank ReDavid
`Litigation Specialist
`Allen & Overy, LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`